Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2018

Open Access 01-12-2018 | Original investigation

Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP

Authors: Annette Masuch, Maik Pietzner, Martin Bahls, Kathrin Budde, Gabi Kastenmüller, Stephanie Zylla, Anna Artati, Jerzy Adamski, Henry Völzke, Marcus Dörr, Stephan B. Felix, Matthias Nauck, Nele Friedrich

Published in: Cardiovascular Diabetology | Issue 1/2018

Login to get access

Abstract

Background

The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is an important biomarker for the diagnosis of heart failure. Apart from this and only recently recognized, NT-proBNP levels associate with higher HDL- and lower LDL-cholesterol levels comprising a favorable blood lipid profile. To further examine this observation, the lipoprotein profile in relation to NT-proBNP was examined in-depth by proton nuclear magnetic resonance spectroscopy (1H-NMR). We complemented this investigation with a state-of-the-art untargeted metabolomics approach.

Methods

Lipoprotein particles were determined by 1H-NMR spectroscopy in 872 subjects without self-reported diabetes from the population-based Study of Health in Pomerania (SHIP)-TREND with available NT-proBNP measurements. Comprehensive metabolomics data for plasma and urine samples were obtained. Linear regression models were performed to assess the associations between serum concentrations of NT-proBNP and the metabolites/lipoprotein particles measured in plasma or urine.

Results

An increase in serum NT-proBNP was associated with a benefical lipoprotein profile, including a decrease in VLDL, IDL and LDL-particles along with an increase in large HDL particles. These findings were replicated in a second independent cohort. Serum concentrations of NT-proBNP showed significant inverse associations with seven plasma metabolites while associations with 39 urinary metabolites, mostly comprising amino acids and related intermediates, were identified. Mediation analyses revealed adiponection as mediating factor for the associations observed with lipoproteins particles.

Conclusions

Most of the metabolic changes associated with NT-proBNP implicate significant influence on the blood lipid profile besides vasodilatory and the diuretic action of BNP signaling. Our data suggest that the more favorable lipoprotein profile as associated with elevated NT-proBNP concentrations in mainly cardiac healthy individuals might relate to adiponectin signaling indicating even indirect cardio-protective effects for NT-proBNP.
Appendix
Available only for authorised users
Literature
1.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefPubMed
2.
Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G, et al. Brain natriuretic peptide: much more than a biomarker. Int J Cardiol. 2016;221:1031–8.CrossRefPubMed
3.
Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res. 2001;51(3):495–509.CrossRefPubMed
4.
5.
Jacob M, Saller T, Chappell D, Rehm M, Welsch U, Becker BF. Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability. Basic Res Cardiol. 2013;108(3):347.CrossRefPubMed
6.
Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14(10):1345–51.CrossRefPubMed
7.
Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014;37(11):2899–908.CrossRefPubMed
8.
Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol. 2013;62(8):752–60.CrossRefPubMed
9.
Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17(1):81–96.CrossRefPubMed
10.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594–600.CrossRefPubMed
11.
He WT, Mori M, Yu XF, Kanda T. Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional study. Lipids Health Dis. 2016;15:3.CrossRefPubMedPubMedCentral
12.
Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, et al. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2014;63(4):475–83.CrossRefPubMed
13.
Sanchez OA, Duprez DA, Daniels LB, Maisel AS, Otvos JD, Peralta CA, et al. The association between N-terminal pro B-type natriuretic peptide and lipoprotein particle concentration plateaus at higher N-terminal pro B-type natriuretic peptide values: Multi-Ethnic Study on Atherosclerosis. Metabolism. 2015;64(8):857–61.CrossRefPubMedPubMedCentral
14.
Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195–211.CrossRefPubMed
15.
Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46(4):660–6.CrossRefPubMed
16.
Spannella F, Giulietti F, Cocci G, Landi L, Borioni E, Lombardi FE, et al. N-terminal pro B-Type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly. Nutr Metab Cardiovasc Dis. 2018;28(6):629–35.CrossRefPubMed
17.
Brutsaert EF, Biggs ML, Delaney JA, Djousse L, Gottdiener JS, Ix JH, et al. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: the cardiovascular health study. Metabolism. 2016;65(10):1489–97.CrossRefPubMedPubMedCentral
18.
Tanaka A, Yoshida H, Kawaguchi A, Oyama JI, Kotooka N, Toyoda S, et al. N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. Sci Rep. 2017;7(1):5810.CrossRefPubMedPubMedCentral
19.
Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294–307.CrossRefPubMed
20.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.CrossRefPubMedPubMedCentral
21.
Volzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis. 2010;209(2):606–10.CrossRefPubMed
22.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358–67.CrossRefPubMed
23.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–70.CrossRefPubMed
24.
Knacke H, Pietzner M, Do KT, Romisch-Margl W, Kastenmuller G, Volker U, et al. Metabolic fingerprints of circulating IGF-1 and the IGF-1/IGFBP-3 ratio: a multifluid metabolomics study. J Clin Endocrinol Metab. 2016;101(12):4730–42.CrossRefPubMed
25.
Pietzner M, Homuth G, Budde K, Lehmphul I, Volker U, Volzke H, et al. Urine Metabolomics by (1)H-NMR spectroscopy indicates associations between serum 3,5-T2 concentrations and intermediary metabolism in euthyroid humans. Eur Thyroid J. 2015;4(Suppl 1):92–100.CrossRefPubMedPubMedCentral
26.
Stone CJ, Koo C-Y. Additive splines in statistics. Proc Stat Comp Sect Am Stat Assoc. 1985;27:45–8.
27.
Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. BMC Syst Biol. 2011;5:21.CrossRefPubMedPubMedCentral
28.
29.
30.
31.
Ohara T, Kim J, Asakura M, Asanuma H, Nakatani S, Hashimura K, et al. Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens Res. 2008;31(5):825–31.CrossRefPubMed
32.
Fiaschi T, Magherini F, Gamberi T, Modesti PA, Modesti A. Adiponectin as a tissue regenerating hormone: more than a metabolic function. Cell Mol Life Sci. 2014;71(10):1917–25.CrossRefPubMed
33.
Jung YR, Lee JH, Sohn KC, Lee Y, Seo YJ, Kim CD, et al. Adiponectin signaling regulates lipid production in human sebocytes. PLoS ONE. 2017;12(1):e0169824.CrossRefPubMedPubMedCentral
34.
Withers SB, Bussey CE, Saxton SN, Melrose HM, Watkins AE, Heagerty AM. Mechanisms of adiponectin-associated perivascular function in vascular disease. Arterioscler Thromb Vasc Biol. 2014;34(8):1637–42.CrossRefPubMed
35.
Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53(22):2070–7.CrossRefPubMed
36.
Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care. 2005;28(9):2181–6.CrossRefPubMed
37.
Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008;57(7):1824–33.CrossRefPubMedPubMedCentral
38.
39.
Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203–30.CrossRefPubMed
40.
Winsz-Szczotka K, Kuznik-Trocha K, Komosinska-Vassev K, Kucharz E, Kotulska A, Olczyk K. Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. Int J Rheum Dis. 2016;19(7):706–14.CrossRefPubMed
41.
Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L, et al. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes. 2015;64(6):2207–19.CrossRefPubMed
42.
Hansen CS, Vistisen D, Jorgensen ME, Witte DR, Brunner EJ, Tabak AG, et al. Adiponectin, biomarkers of inflammation and changes in cardiac autonomic function: whitehall II study. Cardiovasc Diabetol. 2017;16(1):153.CrossRefPubMedPubMedCentral
43.
Kubota M, Yoneda M, Maeda N, Ohno H, Oki K, Funahashi T, et al. Westernization of lifestyle affects quantitative and qualitative changes in adiponectin. Cardiovasc Diabetol. 2017;16(1):83.CrossRefPubMedPubMedCentral
44.
Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, et al. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol. 2016;15(1):153.CrossRefPubMedPubMedCentral
45.
Ortega Moreno L, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:17.CrossRefPubMedPubMedCentral
46.
Wihlborg AK, Malmsjo M, Eyjolfsson A, Gustafsson R, Jacobson K, Erlinge D. Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. Br J Pharmacol. 2003;138(8):1451–8.CrossRefPubMedPubMedCentral
47.
Gallazzini M, Burg MB. What’s new about osmotic regulation of glycerophosphocholine. Physiology (Bethesda). 2009;24:245–9.PubMedPubMedCentral
48.
Sekula P, Goek ON, Quaye L, Barrios C, Levey AS, Romisch-Margl W, et al. A metabolome-wide association study of kidney function and disease in the general population. J Am Soc Nephrol. 2016;27(4):1175–88.CrossRefPubMed
49.
Pietzner M, Kaul A, Henning AK, Kastenmuller G, Artati A, Lerch MM, et al. Comprehensive metabolic profiling of chronic low-grade inflammation among generally healthy individuals. BMC Med. 2017;15(1):210.CrossRefPubMedPubMedCentral
50.
Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem. 2009;55(6):1135–46.CrossRefPubMed
51.
Fuchs D, Stahl-Hennig C, Gruber A, Murr C, Hunsmann G, Wachter H. Neopterin–its clinical use in urinalysis. Kidney Int Suppl. 1994;47:S8–11.PubMed
52.
Holven KB, Retterstol K, Ueland T, Ulven SM, Nenseter MS, Sandvik M, et al. Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype. PLoS ONE. 2013;8(11):e78241.CrossRefPubMedPubMedCentral
53.
Liang F, Kapoun AM, Lam A, Damm DL, Quan D, O’Connell M, et al. B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology. 2007;148(8):3722–9.CrossRefPubMed
54.
Long T, Hicks M, Yu HC, Biggs WH, Kirkness EF, Menni C, et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet. 2017;49(4):568–78.CrossRefPubMed
55.
Rossi GP, Sticchi D, Giuliani L, Bernante P, Zavattiero S, Pessina AC, et al. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med. 2006;17(6):975–80.PubMed
56.
Li P, Sun F, Cao HM, Ma QY, Pan CM, Ma JH, et al. Expression of adiponectin receptors in mouse adrenal glands and the adrenocortical Y-1 cell line: adiponectin regulates steroidogenesis. Biochem Biophys Res Commun. 2009;390(4):1208–13.CrossRefPubMed
57.
58.
Crown SB, Marze N, Antoniewicz MR. Catabolism of branched chain amino acids contributes significantly to synthesis of odd-chain and even-chain fatty acids in 3T3-L1 adipocytes. PLoS ONE. 2015;10(12):e0145850.CrossRefPubMedPubMedCentral
59.
60.
Qiao L, Kinney B, Yoo HS, Lee B, Schaack J, Shao J. Adiponectin increases skeletal muscle mitochondrial biogenesis by suppressing mitogen-activated protein kinase phosphatase-1. Diabetes. 2012;61(6):1463–70.CrossRefPubMedPubMedCentral
61.
Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006;55(9):2562–70.CrossRefPubMed
62.
Coue M, Moro C. Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie. 2016;124:84–91.CrossRefPubMed
63.
Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122(3):1022–36.CrossRefPubMedPubMedCentral
64.
Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17(2):200–5.CrossRefPubMed
65.
Bartelt A, John C, Schaltenberg N, Berbee JFP, Worthmann A, Cherradi ML, et al. Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport. Nat Commun. 2017;8:15010.CrossRefPubMedPubMedCentral
Metadata
Title
Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP
Authors
Annette Masuch
Maik Pietzner
Martin Bahls
Kathrin Budde
Gabi Kastenmüller
Stephanie Zylla
Anna Artati
Jerzy Adamski
Henry Völzke
Marcus Dörr
Stephan B. Felix
Matthias Nauck
Nele Friedrich
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2018
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-018-0765-1

Other articles of this Issue 1/2018

Cardiovascular Diabetology 1/2018 Go to the issue

Original investigation

Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the ‘common soil’ hypothesis

Original investigation

Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study

Original investigation

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes

Review

Association between insulin resistance and the development of cardiovascular disease

Review

Lower extremity arterial disease in patients with diabetes: a contemporary narrative review

Original investigation

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits